Science and Pipeline
Arctic Vision China R&D Progress
Partners R&D Progress
青光眼
待定文字
青光眼，是由于视神经病变导致的一种不可逆的神经退行性疾病，其典型的病理表现为视网膜神经节细胞进行性丢失，
是全球首位不可逆性致盲眼病1。据估计，2020年全球约有7600万青光眼患者，其中仅在我国就可达到2100万1,2。目前最常用的疗法为通
过降低和控制眼压以延缓视神经损害，然而，相当一部分的青光眼患者即使眼压得到控制，视功能损害仍然持续进展。因此，临床迫切需要
开发新作用机制的疗法来治疗和预防青光眼相关的失明。
ADDRESS
@1Suite 906-908, 9F, Tower II, Century Link, 1196 Century Avenue, Shanghai, China
@2Suite A09, 10th Floor, Twin Towers (East), B 12 Jianguomenwai Avenue, Beijing, China
@3Room 1111, 11F., OfficePlus @Prince Edward 794-802 Nathan Road, Kowloon, Hong Kong
@4Suite Level 5 63 Pirie Street, Adelaide, SA 5000, Australia
SUBSCRIBE TO OUR NEWSLETTER
Subscribe
To report a potential adverse event, please refer to the contact information below:
Global: globalsafety@arcticvision.com
Mainland China: safety.cn@arcticvision.com
Hong Kong, China: safety.hk@arcticvision.com
Copyright © 2023 ARCTIC VISION HONG KONG BIOTECH LIMITED